Express Pharma

COVID vaccines induce robust protection against severe disease from Omicron

The research demonstrated that the vaccines induce this protection through cellular immunity or the production of protective immune cells

0 163

Current COVID-19 vaccines provide robust protection against severe disease and hospitalisation caused by both the Delta and Omicron variants, according to a study.

The research, published in the journal Nature recently, demonstrated that the vaccines induce this protection through cellular immunity or the production of protective immune cells, such as so-called killer and memory cells.

Cellular immunity continues to protect from severe COVID-19 disease despite the Omicron variant’s evasion of neutralising antibodies, the researchers said.

The team at Beth Israel Deaconess Medical Center (BIDMC) in Israel assessed samples from 47 individuals vaccinated with either the Johnson and Johnson or Pfizer-BioNTech vaccines.

“Our data provide immunological context for the observation that current vaccines still provide robust protection against severe disease and hospitalisation due to the Omicron variant despite substantially reduced neutralising antibody responses and increased breakthrough infection,” said corresponding author Dan H Barouch.

The researchers used samples from uninfected individuals who received either the Johnson and Johnson or Pfizer vaccines.

They measured CD8 T cell and CD4 T cell responses to the original, Delta and Omicron strains of the SARS-CoV-2 virus after one month and then again after eight months following final vaccination.

Both CD4 and CD8 cells, also known as T cells, are white blood cells that fight infection and play an important role in the immune system.

The team also assessed antibody responses to the variants at one and eight months. Consistent with previous studies, the scientists observed minimal cross-reactive Omicron-specific neutralising antibodies.

In contrast, the data suggested that Omicron-specific CD8 T cell responses were more than 80 per cent cross-reactive compared with the CD8 T cell response to the original strain of the virus.

- Advertisement -